Regeneron Says FDA Approves Dupixent for Atopic Dermatitis in Adolescents
12 March 2019 - 7:33AM
Dow Jones News
By Stephen Nakrosis
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) on
Monday announced the U.S. Food and Drug Administration gave its
approval for Dupixent as a treatment for adolescent patients 12 to
17 years of age with moderate-to-severe atopic dermatitis.
Atopic dermatitis causes skin to become red, itchy and
scaly.
A Phase 3 trial evaluating Dupixent monotherapy in adolescent
patients with uncontrolled moderate-to-severe atopic dermatitis
demonstrated the safety and efficacy generally were consistent with
that previously seen in adult studies, the companies said.
Dupixent also is approved in the U.S. for the treatment of some
adult patients with eczema and for use with other asthma medicines
for maintenance treatment of moderate-to-severe asthma in some
patients people aged 12 years and older.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
March 11, 2019 16:18 ET (20:18 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024